Neuroprotective โ 10mg/vial
$79.76 AUD
One of few peptides with human clinical trial data.
๐ง Need BAC water? 30mL bacteriostatic water available โ $21.90 ($13 less than AU competitors). Add to your order.
Semax is a synthetic heptapeptide derived from the ACTH(4โ7) sequence, developed collaboratively by Moscow State University (MSU) and the Institute of Molecular Genetics (IMG). It is one of the few research peptides with extensive human clinical trial data: Semax is registered as an approved pharmaceutical in Russia and Ukraine for the treatment of ischaemic stroke, transient ischaemic attack (TIA), optic neuropathy, and cognitive impairment.
Its exceptional safety record โ decades of clinical use without significant adverse effects โ and potent neuroprotective activity make it one of the most compelling nootropic research peptides available. The peptide's efficacy in both acute neurological injury and chronic cognitive enhancement research contexts is supported by over 30 years of published studies.
"FOR RESEARCH USE ONLY. This information is provided for scientific and educational purposes only. It does not constitute medical advice or a recommendation for human use."
| Compound | Semax |
| Form | Lyophilized powder |
| Dosage | 10mg/vial |
| Purity | 99%+ (HPLC verified) |
| Testing | Third-party HPLC + MS |
| Storage | 2-8ยฐC (refrigerated) |
| Origin | GMP facility |
Semax's primary mechanism involves potent upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) โ the key trophic proteins responsible for neuronal survival, synaptic plasticity, and neurogenesis. This BDNF/NGF upregulation underpins both its acute neuroprotective and chronic nootropic effects.
It activates dopaminergic and serotonergic receptor pathways, increases hippocampal HIF-1ฮฑ (hypoxia-inducible factor) expression for ischaemia protection, and demonstrates anti-neuroinflammatory activity through inhibition of NF-ฮบB and MAPK pathways. Intranasal administration delivers rapid CNS penetration via olfactory epithelium transport, bypassing the blood-brain barrier entirely โ a key advantage for neurological research.
Every batch independently tested via HPLC and Mass Spectrometry. COAs published on site.
Based in Australia with express shipping nationwide. Discreet, temperature-controlled packaging.
Every batch independently tested via HPLC and Mass Spectrometry. COAs published on site with full batch details.
Semax is one of the very few research peptides with human clinical trial data โ it is a registered pharmaceutical in Russia and Ukraine for stroke, TIA, and cognitive impairment. Its safety record spans decades of clinical use, and it has a well-characterised mechanism (BDNF/NGF upregulation) that is supported by extensive peer-reviewed literature.
Intranasal administration is the standard route โ the peptide reaches the CNS via olfactory epithelium transport, bypassing the blood-brain barrier. Clinical stroke protocols use 12โ18 mcg/kg/day. Nootropic research protocols typically use 300โ600 mcg intranasally, 1โ2 times daily. Some studies use up to 1200 mcg/day in divided doses.
Semax is legal to purchase for legitimate research purposes in Australia. It is not a scheduled substance when intended for research use only. All sales are strictly for laboratory research purposes โ not for human or veterinary consumption.
Semax is HPLC tested by an independent third-party laboratory with results exceeding 99% purity. Our latest batch tested at 99.553% (verified COA available on the Lab Results page). Substandard batches are discarded and never sold.
Enter your email and we'll alert you the moment it's back in stock.